Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO

  Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare
  Finance Executive Robert W. Cook as CFO

Business Wire

IRVINGTON, N.Y. -- April 9, 2014

MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind^® system, an FDA
approved optical diagnostic device that assists dermatologists in the
diagnosis of melanoma, appointed veteran healthcare executive Robert W. Cook
as Chief Financial Officer, filling the position which had been vacant since
December 31, 2013. Mr. Cook brings over 20 years of experience in senior
finance and management leadership roles in the healthcare and pharmaceutical
industries, most recently as SVP and CFO of Immune Pharmaceuticals Inc.
(NASDAQ OMX First North and OTCQX:IMNP), a developer of antibody therapeutics
for cancer treatment, following its merger with EpiCept Corporation (Nasdaq
OMX Stockholm and OTCQX:EPCT).

“Bob brings a wealth of hands-on healthcare industry experience and
accomplishment across key functions such as finance, strategic planning,
business development and public company reporting," said Rose Crane, MELA
Sciences’ President and CEO. “We are very excited to have attracted such an
accomplished professional to support MELA’s strategic transformation.”

“I am very pleased to become the newest member of the MELA management team,
and to be joining the Company at an important point in its repositioning
efforts,” commented Mr. Cook. “There is significant potential at MELA, and I
am eager to get started.”

Mr. Cook spent nine years as SVP and CFO at EpiCept where he was responsible
for finance and accounting, SEC reporting, treasury, and budget, as well as
IR/PR, information technology, facilities, human resources and corporate
administration. He had previously served for six years as EVP and CFO of
Pharmos Corporation, a publicly traded biopharmaceutical company.

Mr. Cook began his career in financial services, initially at The Chase
Manhattan Bank, N.A. including several years as a managing director
responsible for developing business in the U.S. pharmaceutical, medical device
and hospital supply sectors. He subsequently served as a Vice President in the
Healthcare Group at General Electric Capital Commercial Finance, focused on
emerging life science companies.

Mr. Cook earned his Bachelor’s degree in International Finance, magna cum
laude, from The American University in Washington, D.C.

About MELA Sciences, Inc.

MELA Sciences is a medical device company developing dermatology diagnostics
utilizing state-of-the-art optical imaging. The Company’s flagship product is
the MelaFind^® system, an FDA, PMA and CE Mark approved, non-invasive
diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis.
The MelaFind^® system uses a variety of visible to near-infrared light waves
to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It
provides images and data on the relative disorganization of a lesion's cell
structure that provides substantial additional perspective to aid melanoma
diagnosis. MELA is also exploring new potential uses for its core imaging
technology and algorithms.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and may
contain words such as “seeks,” “look forward,” and “there seems” that suggest
future events or trends. These statements are based on our current
expectations and are inherently subject to significant uncertainties and
changes in circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive, market,
regulatory and political factors or conditions affecting the company and the
medical device industry in general, as well as more specific risks and
uncertainties set forth in the company’s SEC reports on Forms 10-Q and 10-K.
Given such uncertainties, any or all of these forward-looking statements may
prove to be incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully review its SEC
disclosures available at and


MELA Sciences, Inc.
Diana Garcia Redruello, 212-518-4226
Catalyst Global
David Collins, Eric Lentini, 212-924-9800
Press spacebar to pause and continue. Press esc to stop.